CAMKK2 Enzyme Knockout in Immune Cells Prevents Diet-Induced Obesity and Diabetes in Mice
Key Insights
Researchers at Monash University and Baylor College of Medicine identified CAMKK2 (search) enzyme as a key regulator that, when switched off in immune cells, protected mice from obesity (search), type 2 diabetes (search), and fatty liver disease (search).
Mice lacking CAMKK2 (search) in macrophages resisted high-fat-diet-induced weight gain, burned more energy, and showed improved glucose tolerance and insulin sensitivity despite consuming the same amount of food.
The study reveals that CAMKK2 (search) knockout promotes anti-inflammatory macrophage profiles and metabolic rewiring that increases fat burning and mitochondrial function in adipose tissue.
Researchers have identified a single enzyme that, when disabled in immune cells, protected mice from diet-induced obesity (search), type 2 diabetes (search), and fatty liver disease (search), potentially opening new therapeutic avenues for metabolic disorders affecting millions worldwide.
The study, conducted by scientists at Monash University in Melbourne and Baylor College of Medicine in Texas, focused on CAMKK2 (search) (calcium/calmodulin-dependent protein kinase kinase 2), an enzyme that serves as a key regulator of energy metabolism and coordinates inflammatory responses in macrophages.
Targeting Macrophage-Driven Inflammation
"Obesity (search) is linked to ongoing, low-level inflammation in key organs that control metabolism, like the liver, fat tissue and muscles, and this kind of inflammation plays a role in conditions such as insulin resistance (search) and type 2 diabetes (search)," said John Scott, PhD, a senior research fellow from the Monash Institute of Pharmaceutical Sciences (search) and one of the study's corresponding authors.
The research addresses a critical global health challenge, as the worldwide prevalence of obesity (search) more than tripled between 1975 and 2022, according to the World Obesity Federation. Scott explained that inflammatory macrophages represent a major driver of metabolic dysfunction, as they switch to a faster but less efficient way of making energy when the body experiences stress from a high-fat diet.
Experimental Design and Key Findings
The researchers genetically engineered mice to lack CAMKK2 (search) specifically in myeloid cells, which include macrophages, neutrophils, and dendritic cells. Both CAMKK2 knockout mice and normal control mice were fed a high-fat diet for several weeks while scientists monitored multiple metabolic parameters including body weight, fat mass, energy expenditure, food intake, blood sugar and insulin responses, tissue analysis, gene expression, and macrophage metabolism.
The results demonstrated that mice without CAMKK2 (search) in macrophages resisted high-fat-diet-induced weight and fat gain. Remarkably, although these mice consumed the same amount of food as controls, they burned significantly more energy. The knockout mice also exhibited lower blood sugar and insulin levels, with substantially improved glucose tolerance and insulin sensitivity.
Metabolic Rewiring and Tissue Remodeling
The absence of CAMKK2 (search) triggered profound changes in macrophage behavior and tissue metabolism. Without the enzyme, macrophages adopted an anti-inflammatory profile, produced fewer inflammatory signals, and demonstrated a preference for burning fat as fuel through increased fatty acid oxidation and improved mitochondrial function.
This metabolic rewiring enhanced mitochondrial activity and energy efficiency throughout the body. The adipose tissue in knockout mice underwent remodeling that showed a "beiging" effect, with upregulated gene programs promoting fat burning and thermogenesis. Additionally, the mice's fat, liver, and muscle tissues handled sugar more effectively, providing protection against fatty liver disease (search).
"Our findings show that when the CAMKK2 (search) gene is removed from certain immune cells (in this case, macrophages), fat tissue shifts its activity in a healthier direction," Scott explained. "The genes in the fat start working in ways that support better metabolism and reduce harmful inflammation."
Therapeutic Implications and Limitations
The research suggests that CAMKK2 (search) represents a promising therapeutic target for treating obesity (search) and related metabolic disorders. Scott noted that the enzyme has "direct control of regulating immune cell and whole-body metabolism," making it an attractive candidate for drug development.
However, the study acknowledges several important limitations. The findings may not fully translate from mouse models to humans, requiring additional validation studies. While macrophages demonstrated increased fat burning in laboratory conditions, researchers could not directly prove this occurred to the same extent in living animals.
Current CAMKK2 (search) inhibitors also present challenges for clinical translation. The compound STO-609, which has been used to inhibit CAMKK2, lacks sufficient selectivity and has poor drug-like properties, making it unsuitable for clinical use.
Broader Therapeutic Potential
Beyond metabolic disorders, the research suggests CAMKK2 (search) inhibition could have wider applications. Since macrophage-driven inflammation contributes to atherosclerosis (search), infections, and certain cancers, targeting this enzyme might provide benefits across multiple disease areas.
The findings indicate that CAMKK2 (search) inhibition in macrophages could help prevent or reverse obesity (search)-related insulin resistance (search), fatty liver disease (search), and other metabolic complications. The study was published in the journal Molecular Metabolism, contributing to the growing understanding of how immune cell metabolism influences whole-body metabolic health.